What is Naloxone?
Naloxone is a potent opioid receptor antagonist that rapidly reverses central nervous system and respiratory depression caused by opioid overdose by competitively blocking mu, kappa, and sigma opioid receptors in the brain, spinal cord, and gastrointestinal system. 1, 2
Mechanism of Action
Naloxone works by competing for opioid receptor sites with the greatest affinity for the mu receptor, displacing opioid molecules and reversing their effects 2. It is essentially a pure antagonist with no agonist properties—meaning it has no morphine-like effects and produces essentially no pharmacologic activity when given to someone without opioids in their system 2, 3.
Clinical Uses
Primary Indication: Opioid Overdose Reversal
Naloxone reverses the life-threatening effects of opioid overdose, including 2:
- Respiratory depression (the most critical effect)
- Central nervous system depression
- Sedation
- Hypotension
It works against natural opioids, synthetic opioids (including fentanyl, methadone, propoxyphene), and mixed agonist-antagonist analgesics like pentazocine, nalbuphine, and butorphanol 2.
Routes of Administration
Naloxone can be administered through multiple routes 1:
- Intravenous (IV): Onset within 2 minutes, shortest duration
- Intramuscular (IM): Slightly slower onset, more prolonged effect than IV
- Intranasal (IN): Effective alternative, especially for lay responders
- Subcutaneous: Less commonly used
- Autoinjector: FDA-approved for lay rescuer use since 2014 1
Higher-concentration intranasal naloxone (2 mg/mL) has similar efficacy to intramuscular administration, while lower-concentration formulations (2 mg/5 mL) may be less effective 4.
Dosing Strategy
The "Goldilocks Principle" - Just the Right Dose
Start low and titrate up to avoid precipitating severe opioid withdrawal while achieving adequate reversal 1, 5:
For respiratory depression (not cardiac arrest):
- Initial dose: 0.04-0.4 mg IV/IM 1, 6
- Pediatric: 0.1 mg/kg IV/IM/SC (children <5 years or <20 kg); 2 mg for children ≥5 years or ≥20 kg 7
- Intranasal: 2 mg, repeat in 3-5 minutes if needed 1
- Escalate to 2 mg IV/IM if initial response inadequate 1
For therapeutic opioid reversal (avoiding complete analgesia reversal):
- Use lower doses: 1-15 mcg/kg 7
The goal is to restore adequate ventilation and protective airway reflexes without provoking severe withdrawal 1.
Critical Clinical Principles
Airway and Breathing Come First
The most important intervention for opioid overdose is opening the airway and providing rescue breaths or bag-mask ventilation—naloxone administration should never delay these basic life support measures 8, 9, 10. Standard CPR takes absolute priority in cardiac arrest, as naloxone has not been proven to improve outcomes during cardiac arrest 8, 10.
When to Use Naloxone
Administer naloxone for patients with suspected opioid overdose who have a definite pulse but no normal breathing or only gasping (respiratory arrest) 8, 10. For cardiac arrest, continue high-quality CPR and only give naloxone if it doesn't delay compressions and ventilations 8.
Duration of Action and Recurrence Risk
A critical pitfall: naloxone's duration of action (45-70 minutes) is often shorter than many opioids, especially long-acting formulations like methadone 6, 2. This means:
- Patients require observation for at least 2 hours after the last naloxone dose 7
- Longer observation (potentially several hours) is needed for long-acting or sustained-release opioid overdoses 8, 9
- Recurrent respiratory depression occurs in up to 72% of patients treated with low-dose IV naloxone 9
- Repeat doses or continuous IV infusion may be necessary 8, 9, 10
Safety Profile and Adverse Effects
Excellent Safety in Non-Dependent Patients
Naloxone has no known harms or major clinical effects when given to patients who are not opioid-intoxicated or dependent 1. It can be administered in large doses with minimal clinical effect in non-opioid-dependent patients 5.
Opioid Withdrawal Syndrome
The main risk is precipitating acute withdrawal in opioid-dependent patients 1, 2:
- Hypertension
- Tachycardia
- Agitation and violent behavior
- Vomiting
- Piloerection (goosebumps)
- Drug cravings
These withdrawal symptoms are rarely life-threatening and can be minimized by using the lowest effective dose 1. This is why starting with 0.04 mg rather than higher doses is recommended for opioid-dependent individuals 6, 5.
Special Populations
Never administer naloxone to newborns whose mothers have long-term opioid use due to risk of seizures and acute withdrawal 7.
Community Distribution and Public Health
Community-based naloxone distribution programs are associated with 25-46% lower opioid overdose death rates 11. Take-home naloxone programs are feasible, widely accepted, and cost-effective 1, 9, 12. The FDA approved naloxone autoinjectors for lay rescuer use, and intranasal formulations have been successfully used by friends, family, and bystanders 1, 12.
Post-Overdose Care
After successful reversal 8, 10:
- Observe in healthcare setting until risk of recurrent toxicity is low
- Monitor vital signs and level of consciousness until normalized
- Consider repeat doses or naloxone infusion if respiratory depression recurs
- Patients are at highest risk for subsequent fatal overdose in the first several days after initial overdose 9